Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
Top Cited Papers
- 7 April 2005
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 20 (5) , 523-539
- https://doi.org/10.1002/mds.20464
Abstract
The objective of this study is to update a previous evidence‐based medicine (EBM) review on Parkinson's disease (PD) treatments, adding January 2001 to January 2004 information. The Movement Disorder Society (MDS) Task Force prepared an EBM review of PD treatments covering data up to January 2001. The authors reviewed Level I (randomized clinical trials) reports of pharmacological and surgical interventions for PD, published as full articles in English (January 2001–January 2004). Inclusion criteria and ranking followed the original program and adhered to EBM methodology. For Efficacy Conclusions, treatments were designated Efficacious, Likely Efficacious, Non‐Efficacious, or Insufficient Data. Four clinical indications were considered for each intervention: prevention of disease progression; treatment of Parkinsonism, as monotherapy and as adjuncts to levodopa where indicated; prevention of motor complications; treatment of motor complications. Twenty‐seven new studies qualified for efficacy review, and others covered new safety issues. Apomorphine, piribedil, unilateral pallidotomy, and subthalamic nucleus stimulation moved upward in efficacy ratings. Rasagiline, was newly rated as Efficacious monotherapy for control of Parkinsonism. New Level I data moved human fetal nigral transplants, as performed to date, from Insufficient Data to Non‐ efficacious for the treatment of Parkinsonism, motor fluctuations, and dyskinesias. Selegiline was reassigned as Non‐efficacious for the prevention of dyskinesias. Other designations did not change. In a field as active in clinical trials as PD, frequent updating of therapy‐based reviews is essential. We consider a 3‐year period a reasonable time frame for published updates and are working to establish a Web‐based mechanism to update the report in an ongoing manner. © 2005 Movement Disorder SocietyKeywords
This publication has 45 references indexed in Scilit:
- Stiff person syndrome with eye movement abnormality, myasthenia gravis, and thymomaJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's diseaseMovement Disorders, 2003
- Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's diseaseMovement Disorders, 2003
- Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2003
- Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled studyMovement Disorders, 2003
- Increased daytime sleepiness in Parkinson's disease: A questionnaire surveyMovement Disorders, 2002
- A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18 F-dopa PET studyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2002
- Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's diseaseMovement Disorders, 2002
- Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre studyJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Randomized trial of tolcapone versus pergolide as add‐on to levodopa therapy in Parkinson's disease patients with motor fluctuationsMovement Disorders, 2001